MC4R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-21. Numbers and descriptions here follow the published literature rather than marketing material.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
=== N-Alkylation === Intramolecular amide N-alkylation of alpha-haloacetamide amides 8 with ethanolic potassium hydroxide using ultrasonication gave the 2,5-diketopiperazines 9, where 8 was obtained by an Ugi reaction between amines, aldehydes, isocyanides, and chloroacetic acid. However this route is limited by epimerization at the stereogenic centre and failure to obtain the 2,5-diketopiperazine ring if R1 = Alkyl.
MMP-19 MMPs 11, 14, 15, 16, and 17 MMP-2 and MMP-9 All the other MMPs Analysis of the catalytic domains in isolation suggests that the catalytic domains evolved further once the major groups had differentiated, as is also indicated by the substrate specificities of the enzymes.
Although Barker had previously worked with White, he was feuding with her over the treatment of an elephant at the Los Angeles Zoo. White instead did not attend and pre-recorded her comments that she was scheduled to make about another awardee, Mark Goodson. That same year, Barker donated $1 million (equivalent to $1.4 million in 2021) to the University of Virginia Law School to support the study of animal rights. He made similar donations to Harvard Law School, Stanford Law School, Georgetown University Law Center, Duke University School of Law, Northwestern University Pritzker School of Law, and University of California, Los Angeles. In 2010, the Sea Shepherd Conservation Society announced that it had purchased and outfitted a ship to interdict Japanese whaling operations in the Southern Ocean using $5 million (equivalent to $7.4 million in 2025) provided by Barker. The ship was then named the MY Bob Barker, and its existence was first revealed when it helped discover the location of the Japanese whaling fleet. Barker participated in several PETA public service announcements over the years, including one that claimed that vegetarian diets prevent Alzheimer's disease. In 2010, he donated $2.5 million (equivalent to $3.7 million in 2025) toward the purchase of office space for the organization in Los Angeles. The Bob Barker Building opened in 2012.
Chondronectin is a high molecular weight collagen matrix protein (~180 kDa), or also known as a glycoprotein, and is most commonly found in human synovial fluid. It is mainly responsible for binding chondrocytes and collagen II substrates together in the extracellular matrix (ECM). Chondronectin is characterized as a trimeric protein, that is linked with disulfide bonds. It also has been noted to appear compact and globular in nature. Chondronectin is responsible for helping anchor chondrocytes, bearing mechanical forces and even maintaining homeostasis on a physiological level. Chondronectin works within tissue, where it joins other proteins to build a strong but flexible framework. This structure helps keep joints stable during movement and repeated pressure. Without adhesive matrix proteins like chondronectin, cartilage tissue would have a harder time handling everyday mechanical stress. Chondronectin acts as a strong binding protein inside the body's joints. It helps attach important cartilage cells directly to tough collagen fibers. These cells main responsibility is maintaining healthy cartilage tissue. This protein helps the surrounding tissue structure stay firm and stable while keeping the cartilage properly organized. Without this important connection, the framework of the joins could gradually lose stability. The protein has a three part molecular shape that helps keep it structurally stable. It remains strong while interacting with nearby matrix tissues and surrounding support components.
Sources: en.wikipedia.org
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes. Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
The Houthis have been accused of detaining, torturing, arresting, and holding incommunicado Baháʼí Faith members on charges of espionage and apostasy, which are punishable by death. Houthi leader Abdel-Malek al-Houthi has targeted Baháʼís in public speeches, and accused the followers of Baháʼí Faith of being "satanic" and agents for the western countries, citing a 2013 fatwa issued by Iran's supreme leader.
=== Patient and public involvement === Besides being participants in a clinical trial, members of the public can be actively collaborate with researchers in designing and conducting clinical research. This is known as patient and public involvement (PPI). Public involvement involves a working partnership between patients, caregivers, people with lived experience, and researchers to shape and influence what is researched and how. PPI can improve the quality of research and make it more relevant and accessible. People with current or past experience of illness can provide a different perspective than professionals and compliment their knowledge. Through their personal knowledge they can identify research topics that are relevant and important to those living with an illness or using a service. They can also help to make the research more grounded in the needs of the specific communities they are part of. Public contributors can also ensure that the research is presented in plain language that is clear to the wider society and the specific groups it is most relevant for.
Sources: en.wikipedia.org
== Professional activities == Tippett's work in cybersecurity has led to roles as speaker, contributor and advisor to government and private sector organizations. From 2003 to 2005, he served on the President's Information Technology Committee (PITAC), established by Congress in 1997 under the High Performance Computing Act of 1991 to "guide the Administration's efforts to accelerate the development and adoption of information technologies vital for American prosperity in the 21st century." The U.S. Chamber of Commerce awarded Tippett its first Leadership in Health Care Award at the Chamber's first annual Health Care Summit (2012) for his leadership of Verizon's incubator. Tippett was also Chief Scientist for ICSA Labs and previously served as president of the International Computer Security Association. Tippett is currently an adjunct professor in the Division of General Medical Sciences at Case Western Reserve University School of Medicine. In November 2017, T.E.N., a technology and information security executive networking and relationship-marketing firm, announced that Tippett received the 2017 ISE® Luminary Leadership Award.
==== Phase I–II ==== A phase I safety trial began on 18 June 2020. On 4 September 2020, data on 76 participants in a phase I–II trial were published, indicating preliminary evidence of safety and an immune response. The results were challenged by international vaccine scientists as being incomplete, suspicious, and unreliable when identical data were reported for many of the trial participants, but the authors responded that there was a small sample size of nine, and the measured results of titration could only take discrete values (800, 1600, 3200, 6400). Coupled with the observation that values tended to reach a plateau after three to four weeks, they contend that it is not unlikely that several participants would show identical results for days 21 to 28.
It is the most popular type of soy sauce in Kyushu region of Japan, which is famous for sweet foods. In some cases, it is more common to find amakuchi shoyu than koikuchi shoyu in Kyushu. Newer varieties of Japanese soy sauce include:
Coolies and POWs known as PIM (Prisonniers Internés Militaires, which is basically the same as POW) were civilians used by the army as logistical support personnel. During the battle of Dien Bien Phu, coolies were in charge of burying the corpses—during the first days only, after they were abandoned, hence giving off a terrible smell, according to veterans—and they had the dangerous job of gathering supply packets delivered in drop zones while the Việt Minh artillery was firing hard to destroy the crates. The Việt Minh also used thousands of coolies to carry the Chu-Luc (regional units) supplies and ammunition during assaults. The PIM were civilian males old enough to join Bảo Đại's army. They were captured in enemy-controlled villages, and those who refused to join the State of Vietnam's army were considered prisoners or used as coolies to support a given regiment.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.